Voclosporin Ameliorates Both Proteinuria and Dyslipidemia in a Model of Noninflammatory Glomerular Disease (KIDNEY WEEK 2023) - Oct 15, 2023 - Abstract #SA-PO975; Pres time: Nov 4, 2023; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Pennsylvania Convention Center; "Rats were gavaged twice daily with vehicle (VEH), VCS (4 mg/kg/dose), or cyclosporine (CsA, 10mg/kg/dose) at clinically relevant doses. A clinically relevant dose of VCS ameliorated PAN-induced proteinuria, hypercoagulopathy, and in situ glomerular injury in a model of non-inflammatory glomerular disease, without apparent exacerbation of NS-associated dyslipidemia. Compared to CsA, VCS more effectively ameliorated proteinuria, hypercoagulopathy, and glomerular injury and led to a better lipid profile."
Dyslipidemia • Glomerulonephritis • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Disease
|
|
Yu Kamigaki1; Julie Dougherty1; Amanda P. Waller1; Linda M. Rehaume2; Katelyn Wolfgang1; Eman Abdelghani1; Bryce A. Kerlin1; William E. Smoyer1
|